公开(公告)号：US20240262857A1

公开(公告)日：2024-08-08

申请号：US18562911

申请日：2022-05-27

申请人： Emory University

发明人： Raymond F. Schinazi ,  Frank Amblard

IPC分类号： C07H19/067 ,  A61K31/7068 ,  A61K45/06 ,  A61P31/14 ,  C07B59/00

CPC分类号： C07H19/067 ,  A61K31/7068 ,  A61K45/06 ,  A61P31/14 ,  C07B59/002 ,  C07B2200/05

摘要： Deuterated and/or methylated N4-hydroxycytidine (NHC) analogs, with deuteration at one or both of the 2′- and 3′-positions on the ribo-sugar moiety and/or methylation of the 3′-positions on the ribo-sugar moiety, pharmaceutical compositions comprising one or more of these compounds, and, optionally, at least one additional therapeutic agent, and methods of treating or preventing infections caused by RNA viruses, curing an infection by an RNA virus, or reducing the biological activity of an RNA virus, are disclosed. Representative RNA viruses include, but are not limited to, Coronaviridae, such as MERSr-CoV, SARS-CoV-1, SARSCoV-2, HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, Picornaviridae, Hepeviridae, Noroviruses, Zika, Dengue, Mayaro, Influenza A and B, Parainfluenza, HCV, Rinovirus, tick-borne viruses, Ebola, Lassa, RSV, adenoviruses, enteroviruses, metapneumoviruses, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), and Chikungunya fever (CHIK).

公开(公告)号：US11963972B2

公开(公告)日：2024-04-23

申请号：US16088017

申请日：2017-03-22

申请人： Emory University

发明人： Raymond F. Schinazi ,  Franck Amblard ,  Bryan D. Cox ,  Leda Bassit ,  Longhu Zhou ,  Christina Gavegnano

IPC分类号： A01N43/04 ,  A61K31/4706 ,  A61K31/53 ,  A61K31/655 ,  A61K31/70 ,  A61K31/7064 ,  A61K31/7068 ,  A61P31/14

CPC分类号： A61K31/7068 ,  A61K31/4706 ,  A61K31/53 ,  A61K31/655 ,  A61K31/7064 ,  A61P31/14

摘要： The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

公开(公告)号：US20230056135A1

公开(公告)日：2023-02-23

申请号：US17281940

申请日：2019-10-04

申请人： Emory University

发明人： Raymond F. Schinazi ,  Franck Amblard ,  Bryan Cox ,  Che Chen ,  Leda Bassit

IPC分类号： C07D207/22 ,  C07D403/12 ,  C07D487/04 ,  C07D417/14 ,  C07D401/14 ,  C07D249/04 ,  C07D417/04 ,  C07D401/04 ,  C07D471/04 ,  C07D471/18 ,  C07D498/18 ,  A61K45/06

摘要： The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

公开(公告)号：US20210395300A1

公开(公告)日：2021-12-23

申请号：US17329670

申请日：2021-05-25

申请人： EMORY UNIVERSITY

发明人： Raymond F. Schinazi ,  Franck Amblard ,  Ladislau Kovari ,  Peng Liu ,  Shaoman Zhou ,  Benjamin D. Kuiper ,  Bradley J. Keusch

IPC分类号： C07K5/065 ,  A61P31/14 ,  A61K38/05 ,  A61K45/06

摘要： The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

公开(公告)号：US11065254B2

公开(公告)日：2021-07-20

申请号：US16815383

申请日：2020-03-11

申请人： Emory University ,  The United States Government as Represented by the Department of Veterans Affairs

发明人： Christina Gavegnano ,  Raymond F. Schinazi

IPC分类号： A61K31/519 ,  A61K31/66 ,  A61K31/70 ,  A61K45/06 ,  A61K31/7072 ,  A61K31/4045 ,  A61K31/52 ,  A61K31/536 ,  A61K31/513

摘要： Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

公开(公告)号：US20210008150A1

公开(公告)日：2021-01-14

申请号：US16894407

申请日：2020-06-05

申请人： Emory University

发明人： Raymond F. Schinazi ,  Keivan Zandi ,  Franck Amblard

IPC分类号： A61K38/06 ,  A61K38/05 ,  A61K45/06 ,  A61K31/675 ,  A61K31/53 ,  A61K31/7072 ,  A61K31/519 ,  C07K5/093 ,  C07K5/087 ,  C07K5/08 ,  C07K5/065

摘要： Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

公开(公告)号：US09809616B2

公开(公告)日：2017-11-07

申请号：US14066461

申请日：2013-10-29

申请人： Cocrystal Pharma, Inc. ,  Emory University

发明人： Franck Amblard ,  Steven J. Coats ,  Raymond F. Schinazi

IPC分类号： A01N43/04 ,  A61K31/07 ,  C07H19/048 ,  C07H19/00 ,  C07H19/06 ,  C07H19/10 ,  C07H19/067 ,  C07H19/11 ,  A61K45/06 ,  A61K31/7068

CPC分类号： C07H19/06 ,  A61K31/7068 ,  A61K45/06 ,  C07H19/067 ,  C07H19/10 ,  C07H19/11

摘要： The compounds are of the class of N4-hydroxycytidine nucleosides, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof, useful in treating HCV or Norovirus infections.

公开(公告)号：US20170029407A1

公开(公告)日：2017-02-02

申请号：US15303277

申请日：2016-04-15

申请人： Cocrystal Pharma, Inc. ,  Emory University

发明人： Steven J. Coats ,  Richard Anthony Whitaker ,  Tamara Rosario McBrayer ,  Junxing Shi ,  Franck Amblard ,  Hongwang Zhang ,  Longhu Zhou ,  Raymond F. Schinazi

IPC分类号： C07D401/14 ,  A61K45/06 ,  A61K31/4178

CPC分类号： C07D401/14 ,  A61K31/4178 ,  A61K45/06 ,  C07D403/14

摘要： The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

摘要翻译： 本发明涉及用于治疗或预防人受试者或其他动物宿主中丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 作为用于治疗或预防HCV感染的药物组合物和方法，化合物也是其药学上可接受的盐，前药和其它衍生物。

公开(公告)号：US20220071957A1

公开(公告)日：2022-03-10

申请号：US17455178

申请日：2021-11-16

申请人： ALIGOS THERAPEUTICS, INC. ,  Emory University

发明人： Sandrine Vendeville ,  David Bernard Smith ,  Leonid Beigelman ,  Vladimir Serebryany ,  Raymond F. Schinazi ,  Franck Amblard ,  Leda Bassit

IPC分类号： A61K31/4025 ,  C07D405/12 ,  A61K31/40 ,  C07D207/34 ,  C07D487/04 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  A61K31/4192

摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11052090B2

公开(公告)日：2021-07-06

申请号：US16788374

申请日：2020-02-12

申请人： Emory University ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

发明人： Raymond F. Schinazi ,  Christina Gavegnano

IPC分类号： A61K38/00 ,  C07K14/00 ,  C07K16/28 ,  C07K14/76 ,  C07K14/765 ,  A61K31/519 ,  A61K45/06 ,  A61K38/08 ,  A61K38/17 ,  A61K38/10 ,  A61P31/14 ,  A61P31/18

摘要： Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.